1. CpG-Induced Myeloid CD11b+Gr-1+ Cells Efficiently Suppress T Cell–Mediated Immunoreactivity and Graft-Versus-Host Disease in a Murine Model of Allogeneic Cell Therapy 
Shoshana Morecki, Yael Gelfand, Elena Yacovlev, Osnat Eizik, Yehudit Shabat, Shimon Slavin 
Biology of Blood and Marrow Transplantation 
Volume 14, Issue 9, Pages (September 2008)
DOI: /j.bbmt
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Accumulation of CD11b+/GR-1+ cells in spleens of CpG-treated mice. CpG or CpG+IFA was injected subcutaneously into C57 mice 6 or 10 days, respectively, before flow cytometry analysis. Injections of non-CpG or non-CpG+IFA or IFA alone served as controls and were given in parallel to their relevant opposite (ie, CpG vs non-CpG and CpG+IFA vs non-CpG+IFA). The results shown represent 1 experiment out of 5 experiments conducted.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Characterization of CD11b+ cells isolated from spleens of GpG+IFA-treated mice. Flow cytometry was carried out on a CD11b+ fraction isolated by magnetic beads from spleens of mice treated with CpG+IFA 10 days earlier. (A) Positive fraction of isolated CD11b cells. (B) Isolated CD11b cells gated for GR-1 cells. (C)-(H) Various phenotypic markers of the CD11b-isolated Gr-1 gated cells. The results shown represent 1 experiment out of 3 experiments conducted.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Distribution of T cells and myeloid cells after CpG treatment. Peripheral blood cells, splenocytes, and lymph node–derived C57 cells were analyzed by flow cytometry to detect T cells (CD3) and/or myeloid cells (CD11b and Gr-1) 10 days after inoculation of CpG+IFA (100 μg). Non-CpG+IFA inoculations served as controls. The results shown represent 1 experiment out of 2 experiments conducted.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
In vitro mitogenic responses of splenocytes pretreated with CpG+IFA. Splenocytes derived from C57 mice treated with either CpG+IFA or non-CpG+IFA 10 days earlier were tested for various mitogenic responses (LPS, Con-A, PMA+Ca++Iono, and anti-CD3). Results are presented as response percentage in relation to 100% response of naïve nontreated splenocytes. Response percentages were calculated from 3HTdR uptake in proliferation assays of 3 days of mitogenic stimulation and 4 days for the MLR of C57-derived T cells responding to BALB splenocytes. P = .049 and .016 for the comparison of non-CpG +IFA and CpG+IFA treatments in the MLR and in response to Con-A, respectively; P = .105, .12, and .235 for the comparison of non-CpG +IFA and CpG+IFA treatments in response to PMA+Ca++Iono, anti-CD3, and LPS, respectively. The results represent the mean ± standard error of 3 separate experiments.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

6. Figure 5
Cytokine secretion after CpG treatment. Splenocytes from C57 mice treated 6 or 10 days earlier with CpG (A) or CpG+IFA (B) were stimulated with Con-A for 48 h. The cytokine levels in the supernatants of the various cultures were measured. The results indicate P = .001, .007, and .36 for the comparison of CpG versus non-CpG for secretion of IL-10, IL-6, and IFN-γ, respectively, and P = .048, .013, and .076 for the comparison of CpG+IFA versus non-CpG+IFA for secretion of IL-10, IL-6, and IFN-γ, respectively.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions